HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO CF PharmTech - The Outlook Is Bleak Due to VBP and Fierce Competition

Pre-IPO Xiamen Jihong Technology (PHIP Updates) - Lack of Sustainable Growth Logic

China Healthcare Weekly (May 25) - Pfizer-3SBio's Record-Breaking Deal, RemeGen's HK$796Mn Placing

China Healthcare Weekly (Nov.24) - 10th VBP, Biotech Valuation Logic, China Resources Reorganization

CPMC Holdings (906.HK) Update - These Are the Reasons Why We Find This Deal "Tricky"

Shanghai Henlius Biotech (2696.HK) Privatization Update - These Are the Potential Risks Behind

China Healthcare Weekly (Nov.17) - TCM VBP New Updates, CR Boya Completes Acquisition of Green Cross

BeiGene (6160.HK/​BGNE.US) 24Q3 - Things Are on Track Despite BRUKINSA’s Disappointing QoQ Growth

Event-Driven

<ul>
<li>2024 NRDL negotiation results were released. Some eye-catching drugs were included this time, which will bring challenges to companies such as <a href="https://www.smartkarma.com/entities/innovent-biologics-inc" target="_blank" data-smartkarma-citation="entities:27452:1" rel="noopener">Innovent</a>, RemeGen, <a href="https://www.smartkarma.com/entities/gan-lee-pharmaceuticals-co-ltd" target="_blank" data-smartkarma-citation="entities:36237:1" rel="noopener">Gan &amp; Lee Pharmaceuticals</a>, <a href="https://www.smartkarma.com/entities/xizang-haisco-pharmaceutical-group-coltd" target="_blank" data-smartkarma-citation="entities:4779:1" rel="noopener">Haisco Pharmaceutical</a>, etc..</li>
<li>There have been a big “expectation gap” for biotech companies in Hong Kong stock market - It's a mismatch between what the market thinks and what's actually happening.</li>
<li>The progress of Henlius’ privatization is still slower-than-expected. We also do not know how this privatization ranks in terms of strategic significance of capital operations within Fosun Pharma's system.</li>
</ul>


2024 NRDL negotiation results were released. Some eye-catching drugs were included this time, which will bring challenges to companies such as Innovent, RemeGen, Gan &amp; Lee Pharmaceuticals, Haisco Pharmaceutical, etc..
There have been a big “expectation gap” for biotech companies in Hong Kong stock market - It's a mismatch between what the market thinks and what's actually happening.
The progress of Henlius’ privatization is still slower-than-expected. We also do not know how this privatization ranks in terms of strategic significance of capital operations within Fosun Pharma's system.


Xizang Haisco Pharmaceutical Group Co (002653 CH)

Shanghai Fosun Pharmaceutical (Group) (2196 HK)

Shanghai Fosun Pharmaceutical (Group) (600196 CH)

中国ヘルスケアウィークリー（12月1日）- 2024年NRDL結果、バイオテクノロジーの期待ギャップ、ヘンリウスの幅広いスプレッド